Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Stefanescu Schmidt AC, et al. Among authors: kereiakes dj. Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835. Epub 2017 Feb 22. Circulation. 2017. PMID: 28228427 Free PMC article. Clinical Trial.
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Kereiakes DJ, et al. J Am Coll Cardiol. 1996 Mar 1;27(3):536-42. doi: 10.1016/0735-1097(95)00500-5. J Am Coll Cardiol. 1996. PMID: 8606262 Free article. Clinical Trial.
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ. Kereiakes DJ, et al. Circulation. 1998 Sep 29;98(13):1268-78. doi: 10.1161/01.cir.98.13.1268. Circulation. 1998. PMID: 9751674 Clinical Trial.
Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial.
Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW Jr. Davidson CJ, et al. Among authors: kereiakes dj. Circulation. 2000 May 9;101(18):2172-7. doi: 10.1161/01.cir.101.18.2172. Circulation. 2000. PMID: 10801758 Clinical Trial.
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Harrington RA, et al. Among authors: kereiakes dj. Circulation. 2000 Aug 15;102(7):728-35. doi: 10.1161/01.cir.102.7.728. Circulation. 2000. PMID: 10942739 Clinical Trial.
Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries.
Baim DS, Cutlip DE, O'Shaughnessy CD, Hermiller JB, Kereiakes DJ, Giambartolomei A, Katz S, Lansky AJ, Fitzpatrick M, Popma JJ, Ho KK, Leon MB, Kuntz RE; NIRVANA Investigators (NIR Vascular Advanced North American Trial). Baim DS, et al. Among authors: kereiakes dj. Am J Cardiol. 2001 Jan 15;87(2):152-6. doi: 10.1016/s0002-9149(00)01307-2. Am J Cardiol. 2001. PMID: 11152830 Clinical Trial.
579 results